부산대학교 도서관

We performed basic and clinical studies on cefozopran (CZOP), a new injectable cephem antibiotic, and obtained the following results.1. The concentrations of CZOP in serum, internal genital organs and retroperitoneal fluid after a single i.v. administration of 1g were examined.The peripheral serum level was 73.3μg/ml (mean) at 15min, decreasing to 15.6μg/ml at 3h after administration.The concentrations in the tissues were 21.3-35.1μg/g at 15 min, decreasing to 7.5-12.4μg/g at 3h after administration.The concentrations in retroperitoneal fluid were 15.4±7.1, 30.4±5.6, 26.9 7.7, 15.5±2.6, 8.4±5.4μg/ml at0.5h, lh, 2h, 4h and 6h after administration.2. In clinical trials, CZOP was administered to 11 patients with obstetric and gynecological infections (4 cases of puerperal intrauterine infection, 1 of endometritis, 1 of septic abortion, 1 of pyosalpinx and 4 of pelvic peritonitis).The results were as follows: 2 cases were judged as excellent, 6 good, 2 poor and 1 unknown. The efficacy rate was 80.0 %. Bacteriologically, 13 organisms were isolated and the eradication rate was 84.6 %(11/13).No side effects were observed in any of the cases. In laboratory findings, transient elevation of liver serum transaminase occurred in 3 patients.We conclude that CZOP is a very useful antibiotic in obstetric and gynecologic infections.